基于非影像信息与序列病历的深度学习模型预测非黑色素瘤皮肤癌
模型AUROC达0.89(95%CI 0.87-0.91),平均敏感度83.1%(3.5%),平均特异度82.3%(4.1%),提示该模型有助于识别高危人群以加强皮肤癌预防。
要点
- 基于3年序列诊断与处方信息的深度学习模型可预测1年内非黑色素瘤皮肤癌风险,AUROC为0.89。
- 原位癌及慢性共病(如退行性骨病、高血压、慢性肾功能不全)是较具判别力的预测因素。
- 曲唑酮、阿卡波糖、全身抗真菌药、他汀类等药物是模型中的高排名判别特征。
核心结论
- 基于非影像多维医疗信息的深度学习模型对非黑色素瘤皮肤癌具有潜在预测价值,可帮助医疗人员定位高危人群以采取更密集的预防措施。
研究设计与样本
- 分析纳入1829例以非黑色素瘤皮肤癌为首诊癌症的患者和7665例无癌随机对照。
- 采用卷积神经网络深度学习方法和逐步特征选择,利用3年临床诊断信息、病历及时间序列信息预测未来1年皮肤癌风险。
主要发现
- 纳入的1829例患者中,女性923例(50.5%),男性906例(49.5%),平均年龄65.3(15.7)岁;7665例对照中,女性3951例(51.5%),男性3714例(48.4%),平均年龄47.5(17.3)岁。
- 使用序列诊断信息和药物处方信息作为时间纳入特征矩阵的1年 incident 非黑色素瘤皮肤癌风险预测模型,AUROC为0.89(95%CI 0.87-0.91),平均敏感度83.1%(3.5%),平均特异度82.3%(4.1%)。
- 皮肤原位癌(AUROC 0.867;损失-2.80%)和其他慢性共病如退行性骨病(AUROC 0.872;损失-2.32%)、高血压(AUROC 0.879;损失-1.53%)、慢性肾功能不全(AUROC 0.879;损失-1.52%)是较具判别力的因素。
- 曲唑酮、阿卡波糖、全身抗真菌药、他汀类、非甾体抗炎药和噻嗪类利尿剂是模型中的高排名判别特征;单独剔除每种药物均导致AUROC下降超过1%,例如曲唑酮(AUROC 0.868;减少2.67%)、阿卡波糖(AUROC 0.870;减少2.50%)、全身抗真菌药(AUROC 0.875;减少1.99%)。
临床怎么用
- 该模型可能辅助医疗人员识别非黑色素瘤皮肤癌高危人群,从而针对性地加强皮肤癌预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A prediction model for new-onset nonmelanoma skin cancer could enhance prevention measures, but few patient data-driven tools exist for more accurate prediction. OBJECTIVE: To use machine learning to develop a prediction model for incident nonmelanoma skin cancer based on large-scale, multidimensional, nonimaging medical information. DESIGN, SETTING, AND PARTICIPANTS: This study used a database comprising 2 million randomly sampled patients from the Taiwan National Health Insurance Research Database from January 1, 1999, to December 31, 2013. A total of 1829 patients with nonmelanoma skin cancer as their first diagnosed cancer and 7665 random controls without cancer were included in the analysis. A convolutional neural network, a deep learning approach, was used to develop a risk prediction model. This risk prediction model used 3-year clinical diagnostic information, medical records, and temporal-sequential information to predict the skin cancer risk of a given patient within the next year. Stepwise feature selection was also performed to investigate important and determining factors of the model. Statistical analysis was performed from November 1, 2016, to October 31, 2018. MAIN OUTCOMES AND MEASURES: Sensitivity, specificity, and area under the receiver operating characteristic (AUROC) curve were used to evaluate the performance of the models. RESULTS: A total of 1829 patients (923 women [50.5%] and 906 men [49.5%]; mean [SD] age, 65.3 [15.7] years) with nonmelanoma skin cancer and 7665 random controls without cancer (3951 women [51.5%] and 3714 men [48.4%]; mean [SD] age, 47.5 [17.3] years) were included in the analysis. The 1-year incident nonmelanoma skin cancer risk prediction model using sequential diagnostic information and drug prescription information as a time-incorporated feature matrix could attain an AUROC of 0.89 (95% CI, 0.87-0.91), with a mean (SD) sensitivity of 83.1% (3.5%) and mean (SD) specificity of 82.3% (4.1%). Carcinoma in situ of skin (AUROC, 0.867; -2.80% loss) and other chronic comorbidities (eg, degenerative osteopathy [AUROC, 0.872; -2.32% loss], hypertension [AUROC, 0.879; -1.53% loss], and chronic kidney insufficiency [AUROC, 0.879; -1.52% loss]) served as more discriminative factors for the prediction. Medications such as trazodone, acarbose, systemic antifungal agents, statins, nonsteroidal anti-inflammatory drugs, and thiazide diuretics were the top-ranking discriminative features in the model; each led to more than a 1% decrease of the AUROC when eliminated individually (eg, trazodone AUROC, 0.868; -2.67% reduction; acarbose AUROC, 0.870; -2.50 reduction; and systemic antifungal agents AUROC, 0.875; -1.99 reduction). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that a risk prediction model may have potential predictive factors for nonmelanoma skin cancer. This model may help health care professionals target high-risk populations for more intensive skin cancer preventive methods.
引用
- Wang HH, Wang YH, Liang CW, et al. Assessment of Deep Learning Using Nonimaging Information and Sequential Medical Records to Develop a Prediction Model for Nonmelanoma Skin Cancer. JAMA Dermatol. 2019. PMID: 31483437. doi:10.1001/jamadermatol.2019.2335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。